Valsts: Amerikas Savienotās Valstis
Valoda: angļu
Klimata pārmaiņas: NLM (National Library of Medicine)
OXCARBAZEPINE (UNII: VZI5B1W380) (OXCARBAZEPINE - UNII:VZI5B1W380)
NCS HealthCare of KY, Inc dba Vangard Labs
OXCARBAZEPINE
OXCARBAZEPINE 300 mg
ORAL
PRESCRIPTION DRUG
Oxcarbazepine tablets are indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and as monotherapy in the treatment of partial seizures in children aged 4 years and above with epilepsy, and as adjunctive therapy in children aged 2 years and above with partial seizures. Oxcarbazepine tablets should not be used in patients with a known hypersensitivity to oxcarbazepine or to any of its components. Oxcarbazepine levels may decrease during pregnancy [see Warnings and Precautions (5.10)]. Pregnancy Category C There are no adequate and well-controlled clinical studies of oxcarbazepine in pregnant women; however, oxcarbazepine is closely related structurally to carbamazepine, which is considered to be teratogenic in humans. Given this fact, and the results of the animal studies described, it is likely that oxcarbazepine is a human teratogen. Oxcarbazepine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
150 mg Film-Coated Tablets: yellow color, capsule-shaped, biconvex, coated tablets scored and debossed with ‘183’ on one side and scored on other side. 300 mg Film-Coated Tablets: yellow color, capsule-shaped, biconvex, coated tablets scored and debossed with ‘184’ on one side and scored on other side. Blistercards of 30: NDC 0615-6594-39 600 mg Film-Coated Tablets: yellow color, capsule-shaped, biconvex, coated tablets scored and debossed with ‘185’ on one side and scored on other side. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature]. Dispense in tight container (USP).
Abbreviated New Drug Application
OXCARBAZEPINE- OXCARBAZEPINE TABLET, FILM COATED NCS HealthCare of KY, Inc dba Vangard Labs ---------- MEDICATION GUIDE Oxcarbazepine Tablets (ox kar baz` e peen) Read this Medication Guide before you start taking oxcarbazepine tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. What is the most important information I should know about oxcarbazepine tablets? Do not stop taking oxcarbazepine tablets without first talking to your healthcare provider. Stopping oxcarbazepine tablets suddenly can cause serious problems. Oxcarbazepine tablets can cause serious side effects, including: 1. Oxcarbazepine tablets may cause the level of sodium in your blood to be low. Symptoms of low blood sodium include: • nausea • tiredness, lack of energy • headache • confusion • more frequent or more severe seizures. Similar symptoms that are not related to low sodium may occur from taking oxcarbazepine tablets. You should tell your healthcare provider if you have any of these side effects and if they bother you or they do not go away. Some other medicines can also cause low sodium in your blood. Be sure to tell your healthcare provider about all the other medicines that you are taking. 2. Oxcarbazepine tablets may also cause allergic reactions or serious problems which may affect organs and other parts of your body like the liver or blood cells. You may or may not have a rash with these types of reactions. Call your healthcare provider right away if you have any of the following: • swelling of your face, eyes, lips, or tongue • trouble swallowing or breathing • a skin rash • hives • fever, swollen glands, or sore throat that do not go away or come and go • painful sores in the mouth or around your eyes • yellowing of your skin or eyes • unusual bruising or bleeding • severe fatigue or weakness • severe muscle pain • frequent infections or infections that do not go Izlasiet visu dokumentu
OXCARBAZEPINE- OXCARBAZEPINE TABLET, FILM COATED NCS HEALTHCARE OF KY, INC DBA VANGARD LABS ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE OXCARBAZEPINE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR OXCARBAZEPINE TABLETS. OXCARBAZEPINE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2000 RECENT MAJOR CHANGES Warnings and Precautions (5.4) 06/2014 INDICATIONS AND USAGE Oxcarbazepine is an antiepileptic drug indicated for: Adults: Monotherapy or adjunctive therapy in the treatment of partial seizures Childre n: Monotherapy in the treatment of partial seizures in children 4 to 16 years Adjunctive therapy in the treatment of partial seizures in children 2 to 16 years (1) DOSAGE AND ADMINISTRATION ADULTS: initiated with a dose of 600 mg/day, given in twice-a-day regimen Adjunctive Therapy: Maximum increment of 600 mg/day at approximately weekly intervals. The recommended daily dose is 1200 mg/day (2.1) Conversion to Monotherapy: Concomitant AEDs should be completely withdrawn over 3 to 6 weeks, while maximum dose of oxcarbazepine should be reached in about 2 to 4 weeks. Maximum increment of 600 mg/day at approximately weekly intervals to a recommended daily dose of 2400 mg/day (2.2) Initiation of Monotherapy: Increments of 300 mg/day every third day to a dose of 1200 mg/day. (2.3) CHILDREN: initiation with 8 to 10 mg/kg/day, given in twice-a-day regimen. For patients aged 2 to <4 years and under 20 kg, a starting dose of 16 to 20 mg/kg/day may be considered. Recommended daily dose is dependent upon patient weight Adjunctive Patients (Aged 2 to 16 Years): For patients aged 4 to 16 years, target maintenance dose should be achieved over 2 weeks (2.4). For patients aged 2 to <4 years, maximum maintenance dose should be achieved over 2 to 4 weeks and should not to exceed 60mg/kg/day (2.4) Conversion to Monotherapy for Patients (Aged 4 to 16 Years) Maximum increment of 10 mg/kg/day at weekly intervals, concomitant antiepileptic drugs can be comp Izlasiet visu dokumentu